EUVIMEDEUVIMED entdecken
Crossref

Treatment of Vulvar Lichen Sclerosus With Topical Ruxolitinib: A Single‐Center Study

Alessia Paganelli iD, Laura Colonna, Biagio Didona, Giovanni Pellacani, Caterina Longo, Cristina Cristofoletti iD, Mauro Picardo iD

The Journal of Dermatology · 2026-11 · 53 (11) · 1691-1695

DOI: 10.1111/1346-8138.70460 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Dermatology, online erschienen am 12.08.2026. Verfasst von Alessia Paganelli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Regenerative and Immunological Dermatology (CEDRI), IDI-IRCCS Istituto Dermopatico Dell'immacolata, Rome, Italy. Hauptthemen laut MEDLINE: Pyrazoles, Vulvar Lichen Sclerosus, Janus Kinase Inhibitors. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lichen sclerosus (LS) is a chronic inflammatory dermatosis of the anogenital region with limited therapeutic options. Emerging evidence implicates dysregulation of the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway in LS pathogenesis, supporting investigation of targeted therapies. We report a series of 6 patients treated with topical ruxolitinib for vulvar LS, applied twice daily. Clinical outcomes were assessed using the Clinical Scoring System (CSS) and Patient Global Assessment (PtGA) over a mean follow‐up of 7.5 months. All patients reported early symptomatic improvement in pruritus and burning. In parallel, PtGA scores showed significant improvement ( p < 0.05). No local or systemic adverse events were observed. These findings suggest that topical JAK–STAT inhibition may represent a steroid‐sparing option for achieving symptomatic improvement in LS, particularly in patients with concomitant autoimmune conditions. Larger controlled studies are warranted to confirm these preliminary observations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazolesVulvar Lichen SclerosusJanus Kinase InhibitorsHumansFemalePyrimidinesNitrilesTreatment OutcomeMiddle AgedAgedAdministration, TopicalAdministration, CutaneousAdultFollow-Up Studies

Stichwörter der Autor:innen

JAK inhibitorinflammationoff‐labelruxolitinibvulvar lichen sclerosus

Substanzen

PyrimidinesruxolitinibPyrazolesNitrilesJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Center for Regenerative and Immunological Dermatology (CEDRI), IDI-IRCCS Istituto Dermopatico Dell'immacolata, Rome, Italy.
  • Department of Life Sciences, Health and Health Professions, Link Campus University, Rome, Italy.
  • Rare Diseases Unit, IDI-IRCCS Istituto Dermopatico Dell'immacolata, Rome, Italy.
  • Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy.
  • Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy.
  • Clinical Trial Center, IDI-IRCCS Istituto Dermopatico Dell'immacolata, Rome, Italy.

ORCID-Profile: Alessia Paganelli, Cristina Cristofoletti, Mauro Picardo

Zitieren

APA

Paganelli, A., Colonna, L., Didona, B., Pellacani, G., Longo, C., Cristofoletti, C., & Picardo, M. (2026). Treatment of Vulvar Lichen Sclerosus With Topical Ruxolitinib: A Single‐Center Study. The Journal of Dermatology, 53(11), 1691-1695. https://doi.org/10.1111/1346-8138.70460

Vancouver

Paganelli A, Colonna L, Didona B, Pellacani G, Longo C, Cristofoletti C, et al. Treatment of Vulvar Lichen Sclerosus With Topical Ruxolitinib: A Single‐Center Study. The Journal of Dermatology. 2026;53(11):1691-1695. doi:10.1111/1346-8138.70460

BibTeX
@article{Paganelli2026,
  author = {Paganelli, Alessia and Colonna, Laura and Didona, Biagio and Pellacani, Giovanni and Longo, Caterina and Cristofoletti, Cristina and Picardo, Mauro},
  title = {Treatment of Vulvar Lichen Sclerosus With Topical Ruxolitinib: A Single‐Center Study},
  journal = {The Journal of Dermatology},
  year = {2026},
  volume = {53},
  number = {11},
  pages = {1691--1695},
  doi = {10.1111/1346-8138.70460}
}
Kostenlos starten →